End Cash: The amount of cash held by the company for the given period.
BioNexus Gene Lab Corp. (BGLC) had End Cash of $2.49M for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
$7.42M |
|
$-2.98M |
|
$6.34M |
|
$1.09M |
|
$10.39M |
|
$-2.97M |
|
$-0.02M |
|
$-2.98M |
|
$-2.98M |
|
$-2.98M |
|
$-2.98M |
|
$-2.98M |
|
$-2.98M |
|
$-2.88M |
|
$-2.71M |
|
1.86M |
|
1.86M |
|
$-1.61 |
|
$-1.61 |
|
| Balance Sheet Financials | |
$5.45M |
|
$1.60M |
|
$3.80M |
|
$9.25M |
|
$0.52M |
|
-- |
|
$0.12M |
|
$0.64M |
|
$8.61M |
|
$8.61M |
|
$8.61M |
|
2.42M |
|
| Cash Flow Statement Financials | |
$-1.84M |
|
$0.94M |
|
$0.30M |
|
$2.89M |
|
|
End Cash |
$2.49M |
$-0.40M |
|
$0.79M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
10.46 |
|
-- |
|
-- |
|
-- |
|
0.01 |
|
14.62% |
|
-39.93% |
|
-38.80% |
|
-36.54% |
|
-40.20% |
|
-40.20% |
|
$-1.88M |
|
-- |
|
-- |
|
-- |
|
0.80 |
|
9.37 |
|
11.44 |
|
31.90 |
|
-34.64% |
|
-34.64% |
|
-32.26% |
|
-34.64% |
|
$3.56 |
|
$-1.01 |
|
$-0.99 |
|